Perimenopause with Multiple Sclerosis: Oestrogen, Symptoms, and HRT
How perimenopause affects MS symptoms, the neuroprotective role of oestrogen, HRT considerations for women with MS, and practical support strategies.
How Perimenopause Affects MS Symptoms
Multiple sclerosis is a condition in which the immune system attacks the myelin sheath that protects nerve fibres, causing a wide range of neurological symptoms that vary in type and severity between individuals. Perimenopause introduces significant hormonal changes that can affect the immune system, the nervous system, and the inflammatory processes that drive MS activity. Many women with MS report a worsening of their symptoms during perimenopause, including increased fatigue, greater cognitive difficulty, worsening bladder symptoms, and more intense spasticity or weakness. Some women also notice that their relapse pattern changes during this time, though the relationship between perimenopause and MS relapses is complex and not fully characterised in the research. Heat sensitivity, which is a common feature of MS, can intersect badly with perimenopausal hot flashes: for some women, a hot flash is enough to temporarily worsen neurological symptoms in a phenomenon known as Uhthoff's phenomenon. Understanding this connection can help women and their neurologists anticipate and manage these interactions more effectively.
Oestrogen's Neuroprotective Role
Oestrogen has well-documented neuroprotective properties that are particularly relevant in the context of MS. It supports the production of myelin, has anti-inflammatory effects on the central nervous system, modulates the activity of immune cells including T-cells and B-cells that are central to MS pathology, and promotes the survival of neurons. These properties help explain observations from clinical and epidemiological research: women with MS often experience a period of relative stability during pregnancy, when oestrogen levels are extremely high, followed by an increased risk of relapses in the postpartum period when oestrogen drops sharply. A similar but more gradual pattern may occur during perimenopause, when oestrogen levels begin their long decline. Some small trials and observational studies have explored the use of oestriol, a weaker form of oestrogen, as an adjunctive treatment in MS, with some promising early signals. This research is not yet at a stage to change clinical practice widely, but it illustrates the genuine biological relevance of oestrogen to MS disease activity and not just to quality of life symptoms.
HRT Considerations for Women with MS
HRT is not contraindicated in MS, and for women experiencing significant perimenopausal symptoms alongside their MS, it is a legitimate and often beneficial option. Given oestrogen's neuroprotective properties, there is a theoretical case that maintaining oestrogen levels through HRT during perimenopause could have benefits beyond just vasomotor symptom relief, though large randomised controlled trials specifically in women with MS have not yet confirmed this. The practical approach is to consider HRT on the same individual risk-benefit basis that applies to any woman, with the addition of discussion with the neurologist about whether HRT might interact with any disease-modifying therapies (DMTs). Most DMTs do not have known interactions with HRT, but it is always worth checking, as new medications continue to enter the MS treatment landscape. Transdermal oestrogen is generally preferred because it avoids the prothrombotic effects of oral oestrogen, which is relevant for women with MS who have any additional mobility limitations that might slightly raise their baseline thrombosis risk. Micronised progesterone is the preferred progestogen. A joint conversation between your neurologist and a menopause specialist provides the most informed basis for a decision.
Managing Symptom Overlap: Fatigue, Cognition, and Bladder
The symptom overlap between MS and perimenopause is substantial, and it can be genuinely difficult to know which condition is driving a particular symptom at any given time. Fatigue is a core MS symptom and is also one of the most common and disruptive perimenopausal symptoms. Sleep disruption from night sweats amplifies MS fatigue significantly, creating a cycle that can be hard to break. Cognitive symptoms, including difficulty with working memory, word-finding problems, and slowed processing, are common in both conditions, and the cumulative effect can be more pronounced than either would produce alone. Bladder symptoms, including urgency, frequency, and incomplete emptying, are extremely common in MS and are also worsened by the loss of oestrogen's support to the bladder and urethral tissues during perimenopause. Managing these overlapping symptoms effectively requires close communication between your neurological care team and your menopause care, ensuring that treatments for one condition do not conflict with those for the other. Pelvic physiotherapy, in particular, can address bladder symptoms that have components from both MS and genitourinary menopause changes.
Lifestyle Approaches That Support Both Conditions
Several lifestyle strategies are supported by evidence for both MS and perimenopausal health, making them high-priority investments for women managing both conditions. Exercise is central to MS management because it preserves mobility, reduces fatigue, supports mood, and may slow some aspects of disease progression. During perimenopause, exercise additionally supports bone density, cardiovascular health, and metabolic function. Cooling strategies during exercise matter for women with heat-sensitive MS: wearing a cooling vest, exercising in cooled environments, and staying well hydrated reduce the risk of Uhthoff's phenomenon during workouts. Vitamin D is important in both MS (where deficiency is associated with increased disease activity) and perimenopause (where it supports bone health and immune function). Many women with MS are already taking vitamin D supplementation, and this is worth reviewing with your medical team if you are not. Omega-3 fatty acids, found in oily fish and algae-based supplements, have anti-inflammatory properties relevant to both conditions. Sleep management, stress reduction, and social connection all support neurological and hormonal health simultaneously.
Getting Coordinated Care Between Neurology and Menopause Services
Women with MS who are entering perimenopause often find that their neurological care and their menopausal care proceed in separate silos, with each team relatively uninformed about what the other is doing. This is not ideal given the significant interactions between the two conditions and their treatments. Actively working to create communication between your MS team and your GP or menopause specialist is worth the effort. This might involve asking your neurologist to include a note in your medical record about your MS medication when you attend a menopause clinic, or requesting that your GP share your HRT prescription and rationale with your neurological team. MS specialist nurses, who are a standard part of MS care in the NHS, can be particularly helpful in facilitating these conversations and flagging concerns between teams. The MS Society and MS Trust both have resources and helplines that can assist with navigating healthcare during perimenopause. You should not need to choose between managing your MS well and managing your menopause well; with coordinated care, both are achievable.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.